4. Masimo ( MASI) develops, manufactures, and markets non-invasive patient monitoring products to improve patient care. Its Masimo Signal Extraction Technology (Masimo SET) provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry. For the third quarter 2011, revenue, including royalties, rose 3% to $104.0 million, vs. 2010 quarter. Product revenue rose 10% to $97.6 million, whereas worldwide end-user business grew 18%. The company shipped 33,400 Masimo SET and Masimo rainbow SET units, expanding worldwide installed base by 16%. For fiscal 2011, MASI estimates total revenue in the range of $436 million to $439 million, including product revenue between $404 million and $407 million, and royalty revenue between $31.5 million and $32.5 million. MASI has received the American Association of Respiratory Care (AARC) prestigious Zenith award for the fourth straight year. Of the 15 analysts covering the stock, 53% recommend a buy and 40% suggest a hold. The stock's average 12-month price target is $25.05, or 37.7% above the current price, according a Bloomberg consensus.